SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001140361-24-016454
Filing Date
2024-03-29
Accepted
2024-03-29 07:55:21
Documents
15
Period of Report
2024-03-29
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K ef20025022_8k.htm   iXBRL 8-K 30064
2 EXHIBIT 99.1 ef20025022_ex99-1.htm EX-99.1 89098
6 image0.jpg GRAPHIC 391508
  Complete submission text file 0001140361-24-016454.txt   806936

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA galt-20240329.xsd EX-101.SCH 3901
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE galt-20240329_lab.xml EX-101.LAB 21966
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE galt-20240329_pre.xml EX-101.PRE 16068
19 EXTRACTED XBRL INSTANCE DOCUMENT ef20025022_8k_htm.xml XML 4243
Mailing Address 4960 PEACHTREE INDUSTRIAL BOULEVARD SUITE 240 NORCROSS GA 30071
Business Address 4960 PEACHTREE INDUSTRIAL BOULEVARD SUITE 240 NORCROSS GA 30071 678-620-3186
GALECTIN THERAPEUTICS INC (Filer) CIK: 0001133416 (see all company filings)

IRS No.: 043562325 | State of Incorp.: NV | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-31791 | Film No.: 24802035
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)